Video
Author(s):
Pashna Munshi, MD, reviews the differences between acute and chronic GVHD.
Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma
Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma
NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
2 Commerce Drive
Cranbury, NJ 08512